Anika Therapeutics, Inc. (ANIK) Profit Margins
Over the twelve months to 2026-06-30, Anika Therapeutics, Inc. (ANIK) had gross margin 62.2%, operating margin -4.2%, net margin -3.1%, free cash flow margin 0.5%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ANIKAnika Therapeutics, Inc.Follow ANIK — free
—
Price chart with a free account
- Market cap
- 286.7M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
| Line | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 58.7% | 59.4% | 69.7% | 80.2% | 77.4% | 76.8% | 75.9% | 70.4% | 74.9% | 52.9% | 56.1% | 64.3% | 68.3% | 63.4% | 56.6% | 62.2% | |
| Operating margin | 21.6% | 27.6% | 43.4% | 58.2% | 51.8% | 49.0% | 40.3% | 20.6% | 29.9% | -21.7% | 1.8% | 3.2% | 0.7% | -4.3% | -9.8% | -4.2% | |
| Net margin | 13.1% | 16.5% | 27.4% | 36.3% | 33.1% | 31.5% | 28.1% | 17.7% | 23.7% | -18.4% | 2.8% | -13.1% | -68.4% | -47.0% | -9.6% | -3.1% | |
| FCF margin | 13.5% | 12.7% | 32.9% | 36.4% | 33.0% | 10.1% | 28.1% | 28.7% | 29.8% | 8.8% | 2.2% | -2.7% | -6.0% | -1.9% | 3.9% | 0.5% |
USD millions · SEC XBRL
Anika Therapeutics, Inc. — questions
- What is Anika Therapeutics, Inc.'s gross margin?
- 62.2% over the twelve months to 2026-06-30.
- What is Anika Therapeutics, Inc.'s operating margin?
- -4.2% over the twelve months to 2026-06-30.
- What is Anika Therapeutics, Inc.'s net profit margin?
- -3.1% over the twelve months to 2026-06-30.
Every figure on this page comes from Anika Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.